WSMCDD-2025

Peng Zhan obtained B.S. and M.Sc. degrees and a Ph.D. in medicinal chemistry from Shandong University, China. Then, he joined the research group of Professor Xinyong Liu as a Lecturer. Then, he worked as a Postdoctoral Fellow funded by JSPS (Japan Society for the Promotion of Science), Japan. Currently he is a full professor in the Institute of Medicinal Chemistry, Shandong University. His research interests involve the discovery of novel antiviral, antigout agents based on rational drug design and combinatorial chemistry approaches as well as innovative exploitation of medicinal chemistry methodologies.His representative achievements include: the anti-AIDS drug candidate K-5a2 was approved for clinical trials; He has identified a class of anti-influenza drug candidates, including I-3B, which is being developed jointly with Qilu Pharmaceutical Co., LTD; He discovered novel HIV capsid inhibitors, HBV core protein inhibitors and piperazine-based anti-coronavirus drug candidates with broad spectrum and high efficiency. He used hydrophobic-tag technology to discover the first-in-class HBV-core protein degraders with improved drug resistance profiles; He identified heterocyclic influenza nucleoprotein inhibitors and six anti-gout drug candidates through phenotypic screening (two anti-gout drug candidates are being developed jointly with two pharmaceutical companies and drug candidate P-7 has been approved for clinical trials). To date, he has published 57 papers as responsible corresponding author. He has applied for and granted 34 patents. He edited two books on antiviral drugs. He won the title of Young Changjiang Scholar of the Ministry of Education, winner of the Outstanding Youth Fund of Shandong Province, and winner of the Young Medicinal Chemistry Award of the Chinese Pharmaceutical Society. He has been ranked among the top 2% of scientists in the world and among the top 100,000 scientists in the world for many years.